240 related articles for article (PubMed ID: 38187082)
1. Prognostic Biomarkers in Pituitary Tumours: A Systematic Review.
Papadimitriou E; Chatzellis E; Dimitriadi A; Kaltsas GA; Theocharis S; Alexandraki KI
touchREV Endocrinol; 2023 Nov; 19(2):42-53. PubMed ID: 38187082
[TBL] [Abstract][Full Text] [Related]
2. The "game" of glial fibrillary acidic and S100 proteins in pituitary adenomas: two players or several?
Cimpean AM; Ceausu AR; Corlan A; Melnic E; Jitariu AA; Raica M
Endokrynol Pol; 2017; 68(4):380-389. PubMed ID: 28660986
[TBL] [Abstract][Full Text] [Related]
3. Expression of pituitary tumour transforming gene (PTTG) and fibroblast growth factor-2 (FGF-2) in human pituitary adenomas: relationships to clinical tumour behaviour.
McCabe CJ; Khaira JS; Boelaert K; Heaney AP; Tannahill LA; Hussain S; Mitchell R; Olliff J; Sheppard MC; Franklyn JA; Gittoes NJ
Clin Endocrinol (Oxf); 2003 Feb; 58(2):141-50. PubMed ID: 12580928
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Factors for Recurrence in Pituitary Adenomas: Recent Progress and Future Directions.
Lu L; Wan X; Xu Y; Chen J; Shu K; Lei T
Diagnostics (Basel); 2022 Apr; 12(4):. PubMed ID: 35454025
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth inhibitor (VEGI) is an independent indicator for invasion in human pituitary adenomas.
Jia W; Sander AJ; Jia G; Ni M; Liu X; Lu R; Jiang WG
Anticancer Res; 2013 Sep; 33(9):3815-22. PubMed ID: 24023314
[TBL] [Abstract][Full Text] [Related]
6. The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas.
Dai C; Liang S; Sun B; Kang J
Front Endocrinol (Lausanne); 2020; 11():608422. PubMed ID: 33362722
[TBL] [Abstract][Full Text] [Related]
7. Expression analysis of cyclins in pituitary adenomas and the normal pituitary gland.
Turner HE; Nagy Z; Sullivan N; Esiri MM; Wass JA
Clin Endocrinol (Oxf); 2000 Sep; 53(3):337-44. PubMed ID: 10971451
[TBL] [Abstract][Full Text] [Related]
8. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
[TBL] [Abstract][Full Text] [Related]
9. Cell cycle dysregulation in pituitary oncogenesis.
Muşat M; Vax VV; Borboli N; Gueorguiev M; Bonner S; Korbonits M; Grossman AB
Front Horm Res; 2004; 32():34-62. PubMed ID: 15281339
[TBL] [Abstract][Full Text] [Related]
10. EGFL7 participates in regulating biological behavior of growth hormone-secreting pituitary adenomas via Notch2/DLL3 signaling pathway.
Wang J; Liu Q; Gao H; Wan D; Li C; Li Z; Zhang Y
Tumour Biol; 2017 Jul; 39(7):1010428317706203. PubMed ID: 28705113
[TBL] [Abstract][Full Text] [Related]
11. Targeting Aggressive Pituitary Adenomas at the Molecular Level-A Review.
Voellger B; Zhang Z; Benzel J; Wang J; Lei T; Nimsky C; Bartsch JW
J Clin Med; 2021 Dec; 11(1):. PubMed ID: 35011868
[TBL] [Abstract][Full Text] [Related]
12. siRNA-mediated silencing of bFGF gene inhibits the proliferation, migration, and invasion of human pituitary adenoma cells.
Zhou K; Fan YD; Duysenbi S; Wu PF; Feng ZH; Qian Z; Zhang TR
Tumour Biol; 2017 Jun; 39(6):1010428317704805. PubMed ID: 28656882
[TBL] [Abstract][Full Text] [Related]
13. What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics.
Gürlek A; Karavitaki N; Ansorge O; Wass JA
Eur J Endocrinol; 2007 Feb; 156(2):143-53. PubMed ID: 17287403
[TBL] [Abstract][Full Text] [Related]
14. Aggressive Cushing's Disease: Molecular Pathology and Its Therapeutic Approach.
Yamamoto M; Nakao T; Ogawa W; Fukuoka H
Front Endocrinol (Lausanne); 2021; 12():650791. PubMed ID: 34220707
[TBL] [Abstract][Full Text] [Related]
15. Clinical, Pathological, and Molecular Factors of Aggressiveness in Lactotroph Tumours.
Trouillas J; Delgrange E; Wierinckx A; Vasiljevic A; Jouanneau E; Burman P; Raverot G
Neuroendocrinology; 2019; 109(1):70-76. PubMed ID: 30943495
[TBL] [Abstract][Full Text] [Related]
16. Co-expression of intermediate filaments glial fibrillary acidic protein and cytokeratin in pituitary adenoma.
Wiesnagrotzki N; Bernreuther C; Saeger W; Flitsch J; Glatzel M; Hagel C
Pituitary; 2021 Feb; 24(1):62-67. PubMed ID: 33001343
[TBL] [Abstract][Full Text] [Related]
17. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
18. Localization of vascular endothelial growth factor (VEGF) receptors in normal and adenomatous pituitaries: detection of a non-endothelial function of VEGF in pituitary tumours.
Onofri C; Theodoropoulou M; Losa M; Uhl E; Lange M; Arzt E; Stalla GK; Renner U
J Endocrinol; 2006 Oct; 191(1):249-61. PubMed ID: 17065408
[TBL] [Abstract][Full Text] [Related]
19. The role of PD-L1 expression in pituitary tumours: lessons from the current literature.
Lopes-Pinto M; Lacerda-Nobre E; Silva AL; Tortosa F; Marques P
Neuroendocrinology; 2024 May; ():. PubMed ID: 38754394
[TBL] [Abstract][Full Text] [Related]
20. Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study.
Filippella M; Galland F; Kujas M; Young J; Faggiano A; Lombardi G; Colao A; Meduri G; Chanson P
Clin Endocrinol (Oxf); 2006 Oct; 65(4):536-43. PubMed ID: 16984249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
